Navigation Links
Omeros Reports Outcome of Phase 3 Trials of OMS103HP
Date:3/31/2011

SEATTLE, March 31, 2011 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today reported the outcome from its Phase 3 program evaluating OMS103HP in patients undergoing arthroscopic anterior cruciate ligament (ACL) reconstruction surgery.  OMS103HP did not meet the pre-specified endpoints of these studies.

No conclusions could be made regarding drug effect due to confounding factors in the studies.

"Given the strength of the data from previous clinical studies of OMS103HP, we are obviously disappointed and surprised by the outcome. Our analysis of the data does not demonstrate a lack of drug effect nor does it appear to undermine the viability of our Phase 3-ready OMS103HP program for meniscectomy surgery," stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros.   "As we learn more from our data analysis, we will provide additional information on our plans for OMS103HP.  In the meantime, we are continuing to advance our pipeline, including our ophthalmology program, for which we recently announced positive Phase 2b data, and our successful GPCR program."

About Omeros' OMS103HP Program

OMS103HP is designed for use during arthroscopic surgery to improve postoperative joint motion and function and reduce postoperative pain.  OMS103HP is a proprietary combination of ketoprofen, amytriptyline and oxymetazoline that is injected into standard arthroscopic irrigation solutions and perfused through the joint in low concentrations during surgery.  

Conference Call and Webcast Today at 5:30 p.m. EDT

Omeros management will host a conference call today, March 31, at 5:30 p.m. EDT (2:30 p.m. Pacific Time) to discuss to
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... DUBLIN , Sept. 2, 2015  Research ... addition of the "An Introduction to the ... 2015)" conference to their offering. ... the European medical device legislation. It will explain ... involvement of Notified Bodies, how to choose one ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6x789c/new_eu ) has ... Legislation (London, UK - November 16-17, 2015)" conference ... EU modules concerning Pharmacovigilance are a major departure in ... Europe . The intention of the course ... examine how they overlap and fit together and what ...
(Date:9/2/2015)... , Sep. 02, 2015 ... announced the addition of Jain PharmaBiotech,s new report ... Companies" to their offering. This ... clinical specialty, aimed at improving patient care by ... adjust the dose of drugs for improving outcome. ...
Breaking Medicine Technology:Global Therapeutic Drug Monitoring Technologies, Markets, and Companies Report 2015 - Updated 2015 Analysis with Forecasts to 2024 2
(Date:9/3/2015)... ... September 03, 2015 , ... Hunters Creek Retrievers is again ... champion AKC Black Lab Puppy. Celebrate Fall 2015 with unlimited Free Hugs and K9 ... to enjoy Thanksgiving and Christmas with an extra big smile. , This adorable ...
(Date:9/3/2015)... ... 03, 2015 , ... AvePoint, the established leader in enabling enterprise ... 4 – AvePoint’s solution for facilitating two-way collaboration and external sharing without ever ... This is the fifth consecutive year an AvePoint product has made the list. ...
(Date:9/3/2015)... WI (PRWEB) , ... September 03, 2015 , ... At ... after becoming dissatisfied with the traditional health care model, where the primary care physician ... of individuals who want to become educated about their health issues and empowered to ...
(Date:9/3/2015)... ... 03, 2015 , ... Leading post-acute electronic medical record (EMR) ... joining the company’s executive leadership team as VP of Product and as VP ... healthcare product and project management. He has been with HealthWyse since 2000 in ...
(Date:9/2/2015)... (PRWEB) , ... September 03, 2015 , ... ... Group and frequently listed among the most influential leaders in healthcare, will offer ... Delivery Coalition, to take place October 15-16, 2015, in Palm Harbor, Florida, at ...
Breaking Medicine News(10 mins):Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 2Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 3Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 2Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 3Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 4Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 2Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 3Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 2Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 3Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 2Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 3
... to reduce risk , , SUNDAY, Jan. 27 (HealthDay News) ... homes through foundation cracks, causes 100 times more deaths ... Agency. , To heighten awareness of that potential danger, ... Month. , Radon is the second leading cause of ...
... particular family of diseases are passed down from mother to ... the disease differing widely. The research, funded by the Wellcome ... risk of developing a mitochondrial disease which can cause muscle ... and animal cells contain many mitochondria, which are involved in ...
... ROLLING MEADOWS, Ill., Jan. 26 The American,Society ... of leaders in the field of cosmetic and ... filed by Public Citizen with the,U.S. Food and ... supports the current labeling of all Botox(R) products,for ...
... CHICAGO, Jan. 25 Continuing its efforts to,educate, ... PATIENT, a,not-for-profit patient-focused organization, is hosting its 25-minute live,call-in ... air on Monday, January 28, at 6:00 PM on ... discussion on how to make the,most out of your ...
... Better Enjoy Her Time with,Friends and Family, SACRAMENTO, ... moved into a senior citizen center to enjoy the ... made it,increasingly difficult for her to go to the ... a power wheelchair donated by The SCOOTER Store,Mrs. Pittman ...
... WellPoint, Inc. (NYSE:,WLP) announced today that senior management ... on January 30, 2008. The presentation is,expected to ... All interested parties are invited to listen to ... and selecting the "Investor,Info" link. Following the ...
Cached Medicine News:Health News:Radon Gas More Deadly Than Carbon Monoxide Poisoning 2Health News:Mitochondrial 'bottleneck' cracked 2Health News:American Society for Dermatologic Surgery Supports Current Labeling of Allergan's Botox(R) Products 2Health News:Making the Most Out of Your Doctor's Visit 2Health News:Disabled Sacramento Woman, 110, Receives Power Wheelchair Donation from The SCOOTER Store 2Health News:WellPoint Announces Appearance at Upcoming Conference 2
XL Cervical Curette comes with a bayonet design and satin black handles having instrument length 9.5" (24 cm), working distance4.1" (10.4 cm) and handle width 0.6" (1.5 cm)....
Bone Curette, 170 mm...
Bone Curette, 145 mm...
Endocrette Endocervical Curette is a stainless-steel curette with closed blade....
Medicine Products: